Back to News

Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022

Press Release September 12, 2022 8:23 AM EDT

Read More

Press Release 18.04.2022 Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer Read more

Press Release 20.09.2021 Fore Biotherapeutics Continues to Build Leadership Team with Executive and Board Appointments Read more

Press Release 19.05.2021 Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments Read more